MedTrace Logo

Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome

NCT02680379 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2018-10-15

No results posted yet for this study

Summary

The purpose of this study is to determine whether Lovastatin, Minocycline and the combination Lovastatin/Minocycline are effective in treating behavioral symptoms in Fragile X individuals.

Conditions

  • Fragile X Syndrome

Interventions

DRUG

Minocycline, then Minocycline/Lovastatin

Participants of this group will take 1 tablet of minocycline 50mg daily for 4 weeks, minocycline 100mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40mg for the following 12 weeks.

DRUG

Lovastatin, then Minocycline/Lovastatin

Participants of this group will take 1 tablet of lovastatin 20 mg daily for 4 weeks, lovastatin 40 mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40 mg for the following 12 weeks.

Sponsors & Collaborators

  • FRAXA Research Foundation

    collaborator OTHER

  • Université de Sherbrooke

    lead OTHER

Principal Investigators

  • François Corbin, MD/PhD · Fragile X Clinic, Centre de recherche du CHUS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-10-31
Completion
2017-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02680379 on ClinicalTrials.gov